Protein Glycosylation: "New-yet-Old" Target for Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32958703.
- Also identified by DOI 10.1158/1078-0432.CCR-20-3364.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The use of checkpoint monotherapy in treating cancer has limited success. Post-translational modifications (PTM) of proteins such as glycosylation might have clinical implications due to distinct modifications found in diseases and its regulatory role in the immunometabolic gene expression. Such novel mechanistic targets hold great promise for combined immunotherapy.<i>See related article by Shi et al., p. 5990</i>.
Medical subject headings
- Neoplasms
- Protein Processing, Post-Translational